and XBRYKâ„¢ (denosumab-dssb; SB16; 120 mg vial), biosimilars referencing Prolia and Xgeva respectively. In addition, the FDA granted a provisional determination for both Ospomyv and Xbryk's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback